BAY61-3606 Affects the Viability of Colon Cancer Cells in a Genotype-Directed Manner
Name
Lau-2012-BAY61-3606 Affects t.pdf
Size
1.56 MB
Format
Adobe PDF
Checksum (MD5)
f6105c37b7ad2191d9cbb8a00b01fdb1
Author(s) • • • • •
Zhang, Tinghu
Kendall, Krystle R.
Gray, Nathanael S.
Haigis, Kevin M.
Lau, Ken S.
Lauffenburger, Douglas A
Date Issued
July 2012
Journal
PLoS ONE
Publisher
Public Library of Science
Citation
Lau, Ken S. et al. “BAY61-3606 Affects the Viability of Colon Cancer Cells in a Genotype-Directed Manner.” Ed. David J. Reiner. PLoS ONE 7.7 (2012): e41343.
Version
Final published version
Abstract
Background:
K-RAS mutation poses a particularly difficult problem for cancer therapy. Activating mutations in K-RAS are common in cancers of the lung, pancreas, and colon and are associated with poor response to therapy. As such, targeted therapies that abrogate K-RAS-induced oncogenicity would be of tremendous value.
Methods:
We searched for small molecule kinase inhibitors that preferentially affect the growth of colorectal cancer cells expressing mutant K-RAS. The mechanism of action of one inhibitor was explored using chemical and genetic approaches.
Results:
We identified BAY61-3606 as an inhibitor of proliferation in colorectal cancer cells expressing mutant forms of K-RAS, but not in isogenic cells expressing wild-type K-RAS. In addition to its anti-proliferative effects in mutant cells, BAY61-3606 exhibited a distinct biological property in wild-type cells in that it conferred sensitivity to inhibition of RAF. In this context, BAY61-3606 acted by inhibiting MAP4K2 (GCK), which normally activates NFκβ signaling in wild-type cells in response to inhibition of RAF. As a result of MAP4K2 inhibition, wild-type cells became sensitive to AZ-628, a RAF inhibitor, when also treated with BAY61-3606.
Conclusions:
These studies indicate that BAY61-3606 exerts distinct biological activities in different genetic contexts.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1371/journal.pone.0041343